GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clinuvel Pharmaceuticals Limited American Depositary Shares CUVL · USD

US listing · 🇺🇸 United States

Compare

5.18

+1.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Clinuvel Pharmaceuticals Limited American Depositary Shares — daily CUVL Delayed
Market value
$261.2m
Last close × shares
Volume
6.9k
Shares, 9 Nov 2026
Price to earnings
10.1
Dividend yield
0.73%

About Clinuvel Pharmaceuticals Limited American Depositary Shares

Its shares trade under the ticker CUVL. In the fiscal year to 30 June 2026, it reported revenue of $67.7m and net income of $24.4m. At that date it held total assets of $212.5m and shareholders' equity of $196.5m.

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Figures and description from our data supplier, not checked against the company's own report.

More about Clinuvel Pharmaceuticals Limited American Depositary Shares →

Latest on Clinuvel Pharmaceuticals Limited American Depositary Shares

Our reporting

We have not reported on Clinuvel Pharmaceuticals Limited American Depositary Shares yet.

Next results

23 Feb 2027

Due on 23 Feb 2027. Analysts expect earnings of 0.18 a share.

Other United States listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Clinuvel Pharmaceuticals Limited American Depositary Shares's ticker?

Clinuvel Pharmaceuticals Limited American Depositary Shares trades as CUVL on its US listing, under ISIN US1887691038.

What was Clinuvel Pharmaceuticals Limited American Depositary Shares's last closing price?

5.18 on 9 Nov 2026. The figure is in USD and is never converted.

When does Clinuvel Pharmaceuticals Limited American Depositary Shares next report results?

Results are expected on 23 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.